Department of Joint Orthopaedics, Yuebei People's Hospital, Shaoguan City, Guangdong Province 512025, China.
Genet Res (Camb). 2022 Jan 27;2022:2766215. doi: 10.1155/2022/2766215. eCollection 2022.
This study aimed to investigate the effect of hemocoagulase combined with platelet-rich plasma (PRP) in total hip replacement (THR) on reducing bleeding and improving knee joint function in the patients with osteoarthritis.
From February 2018 to February 2020, 80 osteoarthritis patients undergoing THR were included in the study, of which 40 cases were treated with PRP and hemocoagulase (test group) in the joint capsule in THR and the other 40 cases received saline and thrombin in the joint capsule after THR (control group). Postoperative drainage and corresponding functional exercise were performed for the two groups 12 hours after operation. The outcome measures including operation time, soft-tissue release, blood routine, drainage volume, perioperative blood loss, postoperative incision inflammation, deep vein thrombosis (DVT), and range of motion (ROM) of the joint were recorded.
The hemoglobin and hematocrit values of the test group on the second postoperative day were significantly higher than those of the control group ( < 0.05). The postoperative drainage volume and perioperative blood loss were significantly lower than those of the control group ( < 0.05). The test group was better than the control group in the ROM of the joint at 7 and 15 days after the operation ( < 0.05). A lower value of prothrombin time and activated partial thromboplastin time was revealed in the test group compared with the control group ( < 0.05). No significant difference in the operation time, intraoperative soft-tissue release, postoperative incision inflammation, incidence of DVT, incidence of deep infection, and ROM at day 90 after THR was found in the two groups ( > 0.05).
The application of hemocoagulase combined with PRP in THR can reduce perioperative blood loss, increase wound healing speed and quality, and improve coagulation and immune function. It is a safe and effective method for the patients with knee osteoarthritis who underwent THR.
本研究旨在探讨在全髋关节置换术(THR)中应用血凝酶联合富血小板血浆(PRP)减少骨关节炎患者出血并改善膝关节功能的效果。
本研究纳入 2018 年 2 月至 2020 年 2 月间 80 例接受 THR 的骨关节炎患者,其中 40 例在 THR 关节囊中应用 PRP 和血凝酶(试验组),另 40 例在 THR 后关节囊中应用生理盐水和凝血酶(对照组)。两组患者术后 12 小时均进行引流和相应的功能锻炼。记录两组患者的手术时间、软组织松解量、血常规、引流量、围手术期出血量、术后切口炎症、深静脉血栓(DVT)和关节活动度(ROM)等。
术后第 2 天,试验组血红蛋白和红细胞压积值明显高于对照组(<0.05)。术后引流量和围手术期出血量明显低于对照组(<0.05)。术后 7 天和 15 天,试验组关节 ROM 明显优于对照组(<0.05)。与对照组相比,试验组凝血酶原时间和活化部分凝血活酶时间较短(<0.05)。两组患者手术时间、术中软组织松解量、术后切口炎症、DVT 发生率、深部感染发生率和 THR 后 90 天 ROM 比较差异均无统计学意义(>0.05)。
在 THR 中应用血凝酶联合 PRP 可减少围手术期出血量,加快伤口愈合速度和质量,改善凝血和免疫功能,是一种安全有效的治疗膝骨关节炎患者 THR 的方法。